Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9561204 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) | |
US9427421 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) | |
US8747894 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 29 January, 2016
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: TABLET, EFFERVESCENT;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10130580 | ARBOR PHARMS LLC | Taste-masked pharmaceutical compositions |
Apr, 2024
(1 year, 2 months from now) | |
US10441554 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(14 years from now) | |
US11160772 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(14 years from now) |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10166181 | ARBOR PHARMS LLC | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 29, 2024 |
Drugs and Companies using TRIPTORELIN PAMOATE ingredient
Market Authorisation Date: 29 June, 2017
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic